Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

IncobotulinumtoxinA (Xeomin®) vs OnabotulimuntoxinA (Botox®) for Treatment of Overactive Bladder Syndrome: Randomized Non-Inferiority Trial

NCT06034288 is registered in ClinicalTrials.gov with Walter Reed National Military Medical Center as lead sponsor.

NCT NCT06034288
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06034288 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
IncobotulinumtoxinA (Xeomin®) vs OnabotulimuntoxinA (Botox®) for Treatment of Overactive Bladder Syndrome: Randomized Non-Inferiority Trial
Lead sponsor
Walter Reed National Military Medical Center
Phase
Phase 2
Overall status
Unknown status
Start date
May 4, 2023
Completion date
September 30, 2024
Enrollment
64 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

overactive bladder syndrome